Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
Enanta Pharmaceuticals, Inc. (ENTA)
Last enanta pharmaceuticals, inc. earnings: 2/6 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.enanta.com/investor-overview
Company Research
Source: Yahoo! Finance
Unfortunately, Enanta Pharmaceuticals delivered a serious earnings miss. Revenues of US$18m were 18% below expectations, and statutory losses ballooned 29% to US$1.58 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year. View our latest analysis for Enanta Pharmaceuticals Following the recent earnings report, the consensus from eight analysts covering Enanta Pharmaceuticals is for revenues of US$68.8m in 2024. This implies a measurable 6.5% decline in revenue compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 21% to US$5.17. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$72.5m and losses of
Show less
Read more
Impact Snapshot
Event Time:
ENTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENTA alerts
High impacting Enanta Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ENTA
News
- ArriVent Appoints Kristine Peterson to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024Business Wire
- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
ENTA
Earnings
- 2/7/24 - Miss
ENTA
Analyst Actions
- 2/8/24 - JP Morgan
ENTA
Sec Filings
- 3/12/24 - Form 8-K
- 3/8/24 - Form 4
- 3/8/24 - Form 4
- ENTA's page on the SEC website